Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Glofitamab Plus Polatuzumab Vedotin for Relapsed/Refractory Large B-Cell Lymphoma
Glofitamab plus Polatuzumab Vedotin demonstrated a high and durable response, with an overall response rate of 78.3% and a median progression-free survival of 12.3 months in heavil
New Indication: Sacituzumab Govitecan for Untreated Advanced Triple Negative Breast Cancer
The ASCENT-03 trial demonstrated that sacituzumab govitecan significantly improved progression-free survival compared to chemotherapy in patients with untreated, advanced triple-ne
New Reference: 9-Year Results for Adjuvant Nivolumab in Melanoma
Nivolumab showed a longer recurrence-free and distant metastasis-free survival compared to ipilimumab at 9 years in patients with resected stage III or IV melanoma. The overall sur
New Indication: Belzutifan for Advanced Pheochromocytoma or Paraganglioma
In the phase 2 LITESPARK-015 trial, Belzutifan demonstrated antitumor activity in advanced pheochromocytoma or paraganglioma with an objective response rate of 26%. The responses w
New Protocol: Capivasertib with Abiraterone for PTEN-Deficient Prostate Cancer
Capivasertib plus abiraterone showed a significant improvement in radiographic progression-free survival compared to placebo in patients with PTEN-deficient metastatic hormone-sens
New Indication: Adjuvant Atezolizumab for ctDNA-Positive Bladder Cancer
In this phase 3 trial, ctDNA-guided adjuvant atezolizumab improved both disease-free survival and overall survival in patients with muscle-invasive bladder cancer compared to place
New Drug: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
Disitamab Vedotin plus Toripalimab significantly improved progression-free and overall survival compared to chemotherapy in untreated HER2-expressing advanced urothelial cancer. Th
New Reference: Neoadjuvant Carboplatin for Triple-Negative Breast Cancer
This phase III trial evaluated the addition of carboplatin to neoadjuvant chemotherapy in triple-negative breast cancer. The addition improved overall survival, particularly in pre
New Reference: Nirogacestat for Desmoid Tumors
Long-term treatment with nirogacestat resulted in an objective response rate of 45.7%. Safety findings showed a decrease in the incidence and severity of treatment-emergent adverse
